- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04293692
Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus
Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus
Study Overview
Detailed Description
Since late December 2019, human pneumonia cases infected by a novel coronavirus (2019-nCoV) were firstly identified in Wuhan, China. As the virus is contagious and of great epidemic, more and more cases have found in other areas of China and abroad. Up to February 24, a total of 77, 779 confirmed cases were reported in China. At present, there is no effective treatment for patients identified with novel coronavirus pneumonia. Therefore, it's urgent to explore more active therapeutic methods to cure the patients.
Recently, some clinical researches about the 2019 novel coronavirus pneumonia published in The Lancet and The New England Journal of Medicine suggested that massive inflammatory cell infiltration and inflammatory cytokines secretion were found in patients' lungs, alveolar epithelial cells and capillary endothelial cells were damaged, causing acute lung injury. It seems that the key to cure the pneumonia is to inhibit the inflammatory response, resulting to reduce the damage of alveolar epithelial cells and endothelial cells and repair the function of the lung.
Mesenchymal stem cells (MSCs) are widely used in basic research and clinical application. They are proved to migrate to damaged tissues, exert anti-inflammatory and immunoregulatory functions, promote the regeneration of damaged tissues and inhibit tissue fibrosis. Studies have shown that MSCs can significantly reduce acute lung injury in mice caused by H9N2 and H5N1 viruses by reducing the levels of proinflammatory cytokines and the recruitment of inflammatory cells into the lungs. Compared with MSCs from other sources, human umbilical cord-derived MSCs (UC-MSCs) have been widely applied to various diseases due to their convenient collection, no ethical controversy, low immunogenicity, and rapid proliferation rate. In our recent research, we confirmed that UC-MSCs can significantly reduce inflammatory cell infiltration and inflammatory factors expression in lung tissue, and significantly protect lung tissue from endotoxin (LPS) -induced acute lung injury in mice.
The purpose of this clinical study is to investigate safety and efficiency of UC-MSCs in treating pneumonia patients infected by 2019-nCoV. The investigators planned to recruit 48 patients aged from 18 to 75 years old and had no severe underlying diseases. In the cell treatment group, 24 patients received 0.5*10E6 UC-MSCs /kg body weight intravenously treatment 4 times every other day besides conventional treatment. In the control group, other 24 patients received conventional treatment plus 4 times of placebo intravenously. The lung CT, blood biochemical examination, lymphocyte subsets, inflammatory factors, 28-days mortality, etc will be evaluated within 24h and 1, 2, 4, 8 weeks after UC-MSCs treatment.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430081
- Puren Hospital Affiliated to Wuhan University of Science and Technology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 18 years old ≤ age ≤ 75years old;
- CT image is characteristic of 2019 novel coronavirus pneumonia;
- Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase chain reaction (RT-PCR);
- In compliance with the 2019-nCoV pneumonia diagnosis standard (according to the novel coronavirus infection pneumonia diagnosis and treatment program (Trial Implementation Version 6) issued by the National Health and Medical Commission, and WHO 2019 new coronavirus guidelines standards): (A) increased breathing rate (≥30 beats / min), difficulty breathing, cyanosis of the lips; (B) in resting state, means oxygen saturation ≤93%; (C) partial pressure of arterial oxygen (PaO2) / Fraction of inspired oxygen (FiO2) ≤300 mmHg (1mmHg = 0.133kPa);
Exclusion Criteria:
- Patients with severe allergies or allergies to stem cells;
- Patients with serious basic diseases that affect survival, including: blood diseases, cachexia, active bleeding, severe malnutrition, etc.;
- Patients with pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia;
- Continuous use of immunosuppressive agents or organ transplants in the past 6 months;
- In vitro life support (ECMO, ECCO2R, RRT);
- Expected deaths within 48 hours, uncontrolled infections;
- Patients with malignant blood-borne diseases such as HIV or syphilis;
- Patient with pregnancy, are planning to become pregnant or breastfeeding;
- Patients with poor compliance and unable to complete the full study;
- The investigator determines that there may be increased risk of the subject or other conditions that interfere with the clinical trial and the judgment of the results (such as excessive stress, sensitivity or cognitive impairment, etc.);
- There are other situations that the researchers think are not suitable to participate in this clinical study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: UC-MSCs treatment group
Participants will receive conventional treatment plus 4 times of 0.5*10E6 UC-MSCs /kg body weight intravenously at Day1, Day3, Day5, Day7).
|
0.5*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7
|
PLACEBO_COMPARATOR: Control group
Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day1, Day3, Day5, Day7.
|
100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Size of lesion area by chest imaging
Time Frame: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Evaluation of Pneumonia change
|
At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Blood oxygen saturation
Time Frame: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Evaluation of Pneumonia change
|
At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of mortality within 28-days
Time Frame: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Marker for efficacy of treatment
|
At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Sequential organ failure assessment
Time Frame: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
0-4 score, the higher the score is, the poor of the prognosis will be.
|
At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Side effects in the UC-MSCs treatment group
Time Frame: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Number of participants with treatment-related adverse events
|
At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Electrocardiogram, the changes of ST-T interval mostly
Time Frame: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Markers of the heart function
|
At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Concentration of C-reactive protein C-reactive protein, immunoglobulin
Time Frame: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Markers of infection
|
At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
CD4+ and CD8+ T cells count
Time Frame: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Marker of Immunology and inflammation
|
At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)
Time Frame: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Marker of Immunology and inflammation
|
At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Concentration of the myocardial enzymes
Time Frame: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Markers of the heart function
|
At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pr20200225
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on UC-MSCs
-
Renmin Hospital of Wuhan UniversityWuhan Hamilton Biotechnology Co., LtdUnknownDiabetic NephropathyChina
-
Wuhan Union Hospital, ChinaWuhan Hamilton Bio-technology Co., Ltd, China.UnknownCOVID-19 | 2019 Novel Coronavirus PneumoniaChina
-
Puren Hospital Affiliated to Wuhan University of...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shanghai... and other collaboratorsUnknown
-
Shanghai East HospitalWithdrawn
-
ZhiYong PengTuohua Biological Technology Co. LtdUnknownPneumonia, Viral | Pneumonia, Ventilator-AssociatedChina
-
Xijing HospitalChanghai Hospital; Southwest Hospital, ChinaUnknownRheumatoid ArthritisChina
-
Beijing 302 HospitalLanZhou University; Chinese PLA General Hospital; Renmin Hospital of Wuhan University and other collaboratorsNot yet recruitingDecompensated CirrhosisChina
-
PT. Prodia Stem Cell IndonesiaRecruitingPolycystic Ovary SyndromeIndonesia
-
The First Affiliated Hospital of Dalian Medical...Unknown
-
Beijing 302 HospitalLanZhou University; Chinese PLA General Hospital; Renmin Hospital of Wuhan University and other collaboratorsRecruitingDecompensated CirrhosisChina